Source: International Congress 2014 – COPD: points to ponder
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Gashynova (Dnipropetrovsk, Ukraine). Plasma surfactant protein D (SP-D) and smoking status in patients with COPD. Eur Respir J 2014; 44: Suppl. 58, 3629

Member's Comments

No comment yet.

Related content which might interest you: Plasma surfactant protein D (SP-D) and comorbidity rate in patients with COPD Source: International Congress 2014 – Predictors Year: 2014 Plasma surfactant protein D (SP-D) and nutritive status in patients with COPD Source: Annual Congress 2013 –COPD treatment and others Year: 2013 Response to the combined therapy in COPD patients (pts) with different plasma surfactant protein D (SPD) level Source: International Congress 2014 – COPD markers Year: 2014 Plasma levels of TIPM-2 in patients with COPD Source: International Congress 2016 – Molecular targets in pulmonary disease Year: 2016 Lung function in never smoking patients with alpha1antitrypsin deficiency Source: Annual Congress 2013 –Lung function tests to monitor airway diseases Year: 2013 The effect of Vitamin D deficiency on lung function in current smoker COPD patients Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014 Differences in COPD: Smokers versus non smokers Source: International Congress 2015 – Asthma and COPD: overlap and exacerbations Year: 2015 Proteinase-inhibitor system state in patients with COPD Source: International Congress 2015 – COPD: chronic disease and comorbidities Year: 2015 Gender differences in COPD patients Source: International Congress 2014 – Clinical presentations Year: 2014 Plasma surfactant protein D (SP-D) in patients (pts) with stable (S) COPD and during COPD acute exacerbation (AE) Source: Annual Congress 2013 –COPD biomarkers Year: 2013 COPD: Plasma surfactant protein-D (SPD) concentration as a predictor of acute exacerbations (AE) probability Source: International Congress 2016 – Features and impact of comorbidities in COPD Year: 2016 COPD: Acute exacerbation (AE) rate and saturation in the patients with different plasma surfactant protein D (SP-D) level Source: Annual Congress 2013 –COPD mechanisms Year: 2013 Serum BNP levels in COPD, asthma-COPD-overlap-syndrome, smokers and never-smokers Source: International Congress 2016 – Systemic biomarkers Year: 2016 Profile of serum vitamin D levels in stable COPD patients Source: International Congress 2016 – Best abstracts in COPD management Year: 2016 Plasma surfactant protein-D (SPD) concentration and severity of airflow limitation in COPD patients (pts) Source: International Congress 2016 – Biomarkers and phenotypes of COPD Year: 2016 Stable state MR-proadrenomedullin level in COPD patients; a validation study Source: International Congress 2014 – Comorbidities Year: 2014 Metabolomic signature in COPD. Plasma and lung tissue comparison identify sphingolipids as potential biomakers Source: International Congress 2014 – Markers Year: 2014 Biomarkers in COPD exacerbation, the role of adiponectin Source: International Congress 2014 – Predictors Year: 2014 The difference between surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with chronic obstructive pulmonary disease acute exacerbations (AE COPD) and community acquired pneumonia (CAP) Source: International Congress 2014 – Clinical presentations Year: 2014 Nicotine dependence and changes in smoking status among smokers - report from the obstructive lung disease in Northern Sweden COPD study Source: Annual Congress 2013 –COPD and tobacco management Year: 2013